Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report)'s stock price traded down 3.4% on Friday . The stock traded as low as $15.88 and last traded at $15.73. 16,371 shares changed hands during trading, a decline of 97% from the average session volume of 469,299 shares. The stock had previously closed at $16.28.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, November 15th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.83.
View Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance
The company has a market cap of $2.17 billion, a PE ratio of -10.76 and a beta of 1.53. The firm's fifty day moving average is $16.79 and its 200 day moving average is $14.85. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.
Insiders Place Their Bets
In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $17.66, for a total transaction of $176,600.00. Following the sale, the insider now owns 183,266 shares of the company's stock, valued at $3,236,477.56. The trade was a 5.17 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04. Following the sale, the chief executive officer now directly owns 575,661 shares in the company, valued at approximately $10,500,056.64. This trade represents a 0.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 392,484 shares of company stock valued at $6,723,523 in the last 90 days. 11.59% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after buying an additional 1,509 shares during the last quarter. Quarry LP lifted its position in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after buying an additional 3,108 shares during the last quarter. Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals in the second quarter valued at about $99,000. Finally, XTX Topco Ltd acquired a new position in Centessa Pharmaceuticals in the second quarter valued at about $148,000. Institutional investors and hedge funds own 82.01% of the company's stock.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Featured Stories
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
